- NCIt
- C40283
Loading cancer entity…
Loading cancer entity…
Clinical trials
57 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 |
| clinicaltrials |
| NCT01861535 | Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia(PITVIN) | completed | Phase 3 | 110 | Medical University of GrazOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT01735006 | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine | completed | Phase 3 | 7,372 | Xiamen UniversityOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02562508 | A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls | completed | Phase 3 | 979 | Jun ZhangOTHER | 1 | Aug 16, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2023source: clinicaltrials